

eFigure 1 Clinical outcome in MOG<sub>35-55</sub> EAE or sham-immunization with and without MOG-IgG augmentation



MOG<sub>35-55</sub> EAE with MOG-IgG administration (grey squares, n=6, 200  $\mu$ g, i.v.) or isotype-matched control antibody (black circles, n=6, 200  $\mu$ g, i.v.) Sham-immunization with MOG-IgG administration (black asterix, n=5, 200  $\mu$ g, i.v.) or isotype IgG (grey triangles, n=5, 200  $\mu$ g, i.v.). Neurological disability was scored daily on a 10-point scale. n=1 experiment. CFA, Complete Freund's adjuvant; EAE, experimental autoimmune encephalomyelitis; MOG, myelin oligodendrocyte glycoprotein; SEM, standard error of mean.

eFigure 2 Correlation analysis of functional and histopathological disease manifestation in anterior visual system



Correlation of visual acuity at the end of experiment (cf. Figure 1B) and **A)** optic nerve demyelination (cf. Figure 3A) or **B)** retinal ganglion cell count (cf. Figure 3E). Anti-FcRn ( $\alpha$ -FcRn, black) and control (IgG, grey) group. Spearman correlation. c/d, cycles per degree; p, p-value; r, Spearman correlation coefficient; ROI, region of interest.